Ningyuan Zhang

Ningyuan Zhang

Auto-generated profile, based on publicly available information

Ningyuan Zhang

Shanghai University of Traditional Chinese Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
LCLinjun Chen
Linjun Chen
XNXiaobei Ni
Xiaobei Ni
ZXZhipeng Xu
Zhipeng Xu
JFJunshun Fang
Junshun Fang
NZNingyuan Zhang
Ningyuan Zhang
DLDong Li
Dong Li

20 May 2019 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
NZNingyuan Zhang
Ningyuan Zhang
YLYunfei Li
Yunfei Li
YLYinghua Lv
Yinghua Lv
LXLing Xu
Ling Xu
JCJunchao Chen
Junchao Chen
QZQingshan Zheng
Qingshan Zheng

7 May 2020 in Research Square
Verified
Preprint
Open access
PDF file
NZNingyuan Zhang
Ningyuan Zhang
XZXijun Zheng
Xijun Zheng
HLHongxia Liu
Hongxia Liu
QZQingshan Zheng
Qingshan Zheng
LLLujin Li
Lujin Li
Background Our objective was to develop a disease progression model for cognitive decline in Alzheimer’s disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on trial design, and geographical regions. Methods Placebo-controlled randomized AD clinical trials were systemically searched in public databases. Longitudinal placebo response (mean change from baseline in the cognitive subscale of the Alzheimer’s Disease Assessment Scale [ADAS-cog]) and the corresponding demographic information were extracted to establish a disease progression model. Covariate screening and subgroup analyses were performed to identify potential factors affecting the disease progression rate. Results A total of 134 publications (140 trials) were included in this model-based meta-analysis. The typical disease progression rate was 5.82 points per year. The baseline ADAS-cog score was included in the final model using an inverse-U type function. Age was found to be negatively correlated with disease progression rate. After correcting the baseline ADAS-cog score and the age effect, no significant difference in disease progression rate was found between trials published before and after 2008, and between trials using add-on design and those that did not use add-on design. However, a significant difference was found among different trial regions. Trials in East Asian countries showed the slowest decline rate and the largest placebo effect. Conclusions Our model successfully quantified AD disease progression by integrating baseline ADAS-cog score and age as important predictors. These factors and geographic location should be considered when optimizing future trial designs and conducting indirect comparisons of clinical outcomes.